Oral gallium maltolate trial for recurrent glioblastoma

ClinicalTrials.gov has published a new trial registration for NCT07515924, an early-phase study of oral gallium maltolate in recurrent glioblastoma. The registry entry documents the trial's objectives, design, eligibility criteria, and investigator information. No regulatory approvals, safety alerts, or enforcement actions are associated with this registration.\n\nSponsors and investigators conducting drug trials for glioblastoma should note this trial as part of the competitive landscape for CNS oncology therapeutics. Patients and advocacy organizations may find this trial relevant for treatment options. The registration provides no new compliance obligations but signals continued interest in gallium-based compounds for brain cancer.